
    
      In this study, all participants will receive cabazitaxel chemotherapy, which is approved as a
      second line chemotherapy for treating metastatic prostate cancer. Standard hormone or
      androgen ablation therapy will also be used as part of the chemohormonal therapy prior to the
      surgery.
    
  